Dexcel Pharma, OMNII enter into PerioChip agreement
Effective February 1, OMNII will be responsible for all sales, marketing and distribution functions for PerioChip.
Dexcel Pharma and OMNII Oral Pharmaceuticals have announced that the companies have entered into a marketing and distribution agreement for PerioChip (chlorhexidine gluconate 2.5 mg.).
Effective February 1, OMNII will be responsible for all sales, marketing and distribution functions for PerioChip, the only locally applied non-antibiotic, antimicrobial treatment indicated as part of a periodontal maintenance program.
PerioChip, indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis, was first introduced into the United States dental market in 1998. Room temperature PerioChip, which provides the added benefit of being easy to store and simple to use, was introduced in 2002.
"Dexcel Pharma and OMNII Oral Pharmaceuticals share the common goal of providing innovative preventive care treatment options for dental professionals," said Mr. Dan Oren, President and CEO of Dexcel. "OMNII has a proven track record of working with dental professionals through a nationwide team of Preventive Care Consultants and we look forward to be working with the excellent sales force."
Chuck Jackson, CEO of OMNII added, "PerioChip is an excellent addition to the complete line of preventive care products we offer to dental professionals. Dexcel has built a prestigious international reputation by developing unique and innovative health care technologies for over 35 years. We are pleased to be working with a group of such highly talented people."
To order PerioChip, please call OMNII Oral Pharmaceuticals at (866) PERIOCHIP (1-866-737-4624) or (800) 445-3386. For additional information, please contact OMNII Customer Service at (800) 445-3386.